<p>Lyell Immunopharma（纳斯达克代码：LYEL - 获取免费报告）预计将在 2026 年 5 月 12 日星期二市场开盘前公布其 2026 年第一季度的业绩。分析师预计该公司将公布每股收益为（$2.3650）和该季度收入为$0.0060 百万。投资者可以在公司即将发布的 2026 年第一季度财报页面找到电话会议的详细信息，最新的电话会议安排在 2026 年 5 月 13 日星期三东部时间下午 4:00。</p>
<p>获取 <strong>Lyell Immunopharma</strong> 的提醒：</p>
<p>Lyell Immunopharma（纳斯达克代码：LYEL - 获取免费报告）最近一次公布季度财报是在 3 月 12 日星期四。该公司报告的季度每股收益为（$7.68），低于分析师共识预期的（$2.15），差距为（$5.53）。该季度的收入为$0.01 百万，而分析师预期为$0.02 百万。Lyell Immunopharma 的净利润率为负 762,355.56%，股本回报率为负 90.52%。平均而言，分析师预计 Lyell Immunopharma 在当前财政年度的每股收益为$-10，在下一个财政年度的每股收益为$-12。</p>
<h2>Lyell Immunopharma 股票表现</h2>
<p>在周二的交易时段，LYEL 的股价下跌$0.35，达到$20.37。该公司交易了 25,050 股，较其平均交易量 96,931 股有所减少。该股票的 50 日移动平均线为$22.30，200 日移动平均线为$23.45。该股票的市值为$4.7523 亿，市盈率为-1.25，贝塔值为-0.05。Lyell Immunopharma 的 1 年最低价为$7.65，最高价为$45.00。</p>
<h2>分析师评级调整</h2>
<p>一些研究分析师最近对 LYEL 股票发表了评论。华尔街 Zen 在周六的研究报告中将 Lyell Immunopharma 的股票评级从 “持有” 下调至 “卖出”。Zacks Research 在 4 月 7 日星期二的研究报告中将 Lyell Immunopharma 的股票评级从 “持有” 下调至 “强烈卖出”。Citizens Jmp 在 3 月 9 日星期一的研究报告中开始覆盖 Lyell Immunopharma 的股票。他们给予该股票 “市场表现优于大盘” 的评级，目标价为$34.00。Needham &amp; Company LLC 在 4 月 10 日星期五的研究报告中开始覆盖 Lyell Immunopharma 的股票。他们给予该股票 “买入” 评级，目标价为$44.00。最后，Robert W. Baird 在周四的研究报告中为 Lyell Immunopharma 的股票设定了$49.00 的目标价，并给予公司 “表现优于大盘” 的评级。一位研究分析师给予该股票 “强烈买入” 评级，三位给予 “买入” 评级，两位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，共识目标价为$43.00。</p>
<p><strong>阅读我们关于 Lyell Immunopharma 的最新报告</strong></p>
<h2>Lyell Immunopharma 的内部交易活动</h2>
<p>在相关消息中，内部人士 Gary K. Lee 在 2 月 11 日星期三出售了 1,671 股公司的股票。股票以平均价格$23.39 出售，总价值为$39,084.69。出售后，内部人士持有公司的 16,938 股股票，价值为$396,179.82。此次交易使其持股减少了 8.98%。该交易在与 SEC 的法律文件中披露，相关信息可通过此超链接获取。此外，首席执行官 Lynn Seely 在 2 月 11 日星期三出售了 7,455 股公司的股票。股票以平均价格$23.39 出售，总交易额为$174,372.45。出售完成后，首席执行官直接持有公司的 74,266 股股票，价值约为$1,737,081.74。此次交易使其持股减少了 9.12%。该出售的 SEC 文件提供了更多信息。内部人士在上个季度共出售了 11,310 股公司股票，价值为$264,285。公司内部人士持有 6.20% 的股票。</p>
<h2>Lyell Immunopharma 的机构交易</h2>
<p>大型投资者最近增加或减少了在公司的持股。ExodusPoint Capital Management LP 在第四季度购买了 Lyell Immunopharma 的新股份，价值约为$262,000。Marshall Wace LLP 在第二季度购买了 Lyell Immunopharma 的新股份，价值约为$94,000。Jane Street Group LLC 在第四季度购买了 Lyell Immunopharma 的新股份，价值约为$382,000。巴克莱银行在第四季度将其在 Lyell Immunopharma 的持股增加了 1,239.5%。巴克莱银行现在持有该公司 15,967 股股票，价值$491,000，此前在上个季度又购买了 14,775 股。最后，Bridgeway Capital Management LLC 在第二季度购买了 Lyell Immunopharma 的新股份，价值约为$159,000。66.05% 的股票由机构投资者持有。</p>
<h2>Lyell Immunopharma 公司简介</h2>
<p>（获取免费报告）</p>
<p>Lyell Immunopharma 是一家临床阶段的生物技术公司，专注于开发下一代 T 细胞疗法用于癌症治疗。该公司利用一个结合了细胞疗法、基因编辑和分子发现的专有平台，旨在克服治疗实体肿瘤的关键障碍。公司的方法集中在工程化 T 细胞，以增强其持久性、功能性和对免疫抑制肿瘤微环境的抵抗力。</p>
<p>公司的产品管线包括多个自体 T 细胞项目，旨在针对黑色素瘤、卵巢癌和胰腺癌等实体恶性肿瘤中的肿瘤相关抗原。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票超过 Lyell Immunopharma</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TFlFTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TFlFTA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Lyell Immunopharma 吗？</h2>
<p>在考虑 Lyell Immunopharma 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Lyell Immunopharma 并不在名单上。</p>
<p>虽然 Lyell Immunopharma 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

LYEL

<p>Lyell Immunopharma（纳斯达克代码：LYEL）计划于 5 月 12 日发布 2026 年第一季度财报，分析师预测每股亏损为 2.3650 美元，收入为 0.0060 百万美元。该公司此前报告 2025 年第一季度每股亏损 7.68 美元，未能达到预期。LYEL 股票最近交易价格为 20.37 美元，下跌 0.35 美元，市值为 4.7523 亿美元。分析师对该股票的评级不一，普遍评级为 “适度买入”，目标价格为 43.00 美元。内部交易活动近期出现了显著的股票出售</p>

<p>Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) is expected to announce its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of ($2.3650) per share and revenue of $0.0060 million for the quarter. Investors can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:00 PM ET.</p>
<div class="lb-trans"><p>Lyell Immunopharma（纳斯达克代码：LYEL - 获取免费报告）预计将在 2026 年 5 月 12 日星期二市场开盘前公布其 2026 年第一季度的业绩。分析师预计该公司将公布每股收益为（$2.3650）和该季度收入为$0.0060 百万。投资者可以在公司即将发布的 2026 年第一季度财报页面找到电话会议的详细信息，最新的电话会议安排在 2026 年 5 月 13 日星期三东部时间下午 4:00。</p>
</div><p>Get <strong>Lyell Immunopharma</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Lyell Immunopharma</strong> 的提醒：</p>
</div><p>Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last announced its quarterly earnings data on Thursday, March 12th. The company reported ($7.68) EPS for the quarter, missing analysts' consensus estimates of ($2.15) by ($5.53). The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.02 million. Lyell Immunopharma had a negative net margin of 762,355.56% and a negative return on equity of 90.52%. On average, analysts expect Lyell Immunopharma to post $-10 EPS for the current fiscal year and $-12 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>Lyell Immunopharma（纳斯达克代码：LYEL - 获取免费报告）最近一次公布季度财报是在 3 月 12 日星期四。该公司报告的季度每股收益为（$7.68），低于分析师共识预期的（$2.15），差距为（$5.53）。该季度的收入为$0.01 百万，而分析师预期为$0.02 百万。Lyell Immunopharma 的净利润率为负 762,355.56%，股本回报率为负 90.52%。平均而言，分析师预计 Lyell Immunopharma 在当前财政年度的每股收益为$-10，在下一个财政年度的每股收益为$-12。</p>
</div><h2>Lyell Immunopharma Stock Performance</h2>
<div class="lb-trans"><h2>Lyell Immunopharma 股票表现</h2>
</div><p>Shares of LYEL traded down $0.35 during trading hours on Tuesday, reaching $20.37. 25,050 shares of the company traded hands, compared to its average volume of 96,931. The stock's fifty day moving average is $22.30 and its 200 day moving average is $23.45. The stock has a market cap of $475.23 million, a P/E ratio of -1.25 and a beta of -0.05. Lyell Immunopharma has a 1-year low of $7.65 and a 1-year high of $45.00.</p>
<div class="lb-trans"><p>在周二的交易时段，LYEL 的股价下跌$0.35，达到$20.37。该公司交易了 25,050 股，较其平均交易量 96,931 股有所减少。该股票的 50 日移动平均线为$22.30，200 日移动平均线为$23.45。该股票的市值为$4.7523 亿，市盈率为-1.25，贝塔值为-0.05。Lyell Immunopharma 的 1 年最低价为$7.65，最高价为$45.00。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><p>A number of research analysts have recently commented on LYEL shares. Wall Street Zen lowered shares of Lyell Immunopharma from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday. Zacks Research lowered shares of Lyell Immunopharma from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a research report on Tuesday, April 7th. Citizens Jmp began coverage on shares of Lyell Immunopharma in a research note on Monday, March 9th. They issued a &#34;market outperform&#34; rating and a $34.00 target price on the stock. Needham &amp; Company LLC began coverage on shares of Lyell Immunopharma in a research note on Friday, April 10th. They issued a &#34;buy&#34; rating and a $44.00 target price on the stock. Finally, Robert W. Baird set a $49.00 target price on shares of Lyell Immunopharma and gave the company an &#34;outperform&#34; rating in a research note on Thursday. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $43.00.</p>
<div class="lb-trans"><p>一些研究分析师最近对 LYEL 股票发表了评论。华尔街 Zen 在周六的研究报告中将 Lyell Immunopharma 的股票评级从 “持有” 下调至 “卖出”。Zacks Research 在 4 月 7 日星期二的研究报告中将 Lyell Immunopharma 的股票评级从 “持有” 下调至 “强烈卖出”。Citizens Jmp 在 3 月 9 日星期一的研究报告中开始覆盖 Lyell Immunopharma 的股票。他们给予该股票 “市场表现优于大盘” 的评级，目标价为$34.00。Needham &amp; Company LLC 在 4 月 10 日星期五的研究报告中开始覆盖 Lyell Immunopharma 的股票。他们给予该股票 “买入” 评级，目标价为$44.00。最后，Robert W. Baird 在周四的研究报告中为 Lyell Immunopharma 的股票设定了$49.00 的目标价，并给予公司 “表现优于大盘” 的评级。一位研究分析师给予该股票 “强烈买入” 评级，三位给予 “买入” 评级，两位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，共识目标价为$43.00。</p>
</div><p><strong>Read Our Latest Report on Lyell Immunopharma</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Lyell Immunopharma 的最新报告</strong></p>
</div><h2>Insider Activity at Lyell Immunopharma</h2>
<div class="lb-trans"><h2>Lyell Immunopharma 的内部交易活动</h2>
</div><p>In related news, insider Gary K. Lee sold 1,671 shares of the company's stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $23.39, for a total value of $39,084.69. Following the sale, the insider owned 16,938 shares of the company's stock, valued at $396,179.82. The trade was a 8.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Lynn Seely sold 7,455 shares of the company's stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $23.39, for a total transaction of $174,372.45. Following the completion of the sale, the chief executive officer directly owned 74,266 shares in the company, valued at approximately $1,737,081.74. The trade was a 9.12% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 11,310 shares of company stock valued at $264,285 over the last quarter. 6.20% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在相关消息中，内部人士 Gary K. Lee 在 2 月 11 日星期三出售了 1,671 股公司的股票。股票以平均价格$23.39 出售，总价值为$39,084.69。出售后，内部人士持有公司的 16,938 股股票，价值为$396,179.82。此次交易使其持股减少了 8.98%。该交易在与 SEC 的法律文件中披露，相关信息可通过此超链接获取。此外，首席执行官 Lynn Seely 在 2 月 11 日星期三出售了 7,455 股公司的股票。股票以平均价格$23.39 出售，总交易额为$174,372.45。出售完成后，首席执行官直接持有公司的 74,266 股股票，价值约为$1,737,081.74。此次交易使其持股减少了 9.12%。该出售的 SEC 文件提供了更多信息。内部人士在上个季度共出售了 11,310 股公司股票，价值为$264,285。公司内部人士持有 6.20% 的股票。</p>
</div><h2>Institutional Trading of Lyell Immunopharma</h2>
<div class="lb-trans"><h2>Lyell Immunopharma 的机构交易</h2>
</div><p>Large investors have recently added to or reduced their stakes in the company. ExodusPoint Capital Management LP bought a new stake in Lyell Immunopharma during the fourth quarter worth about $262,000. Marshall Wace LLP bought a new stake in Lyell Immunopharma during the second quarter worth about $94,000. Jane Street Group LLC bought a new stake in Lyell Immunopharma during the fourth quarter worth about $382,000. Barclays PLC grew its stake in Lyell Immunopharma by 1,239.5% during the fourth quarter. Barclays PLC now owns 15,967 shares of the company's stock worth $491,000 after buying an additional 14,775 shares during the last quarter. Finally, Bridgeway Capital Management LLC bought a new stake in Lyell Immunopharma during the second quarter worth about $159,000. 66.05% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>大型投资者最近增加或减少了在公司的持股。ExodusPoint Capital Management LP 在第四季度购买了 Lyell Immunopharma 的新股份，价值约为$262,000。Marshall Wace LLP 在第二季度购买了 Lyell Immunopharma 的新股份，价值约为$94,000。Jane Street Group LLC 在第四季度购买了 Lyell Immunopharma 的新股份，价值约为$382,000。巴克莱银行在第四季度将其在 Lyell Immunopharma 的持股增加了 1,239.5%。巴克莱银行现在持有该公司 15,967 股股票，价值$491,000，此前在上个季度又购买了 14,775 股。最后，Bridgeway Capital Management LLC 在第二季度购买了 Lyell Immunopharma 的新股份，价值约为$159,000。66.05% 的股票由机构投资者持有。</p>
</div><h2>Lyell Immunopharma Company Profile</h2>
<div class="lb-trans"><h2>Lyell Immunopharma 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company's approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.</p>
<div class="lb-trans"><p>Lyell Immunopharma 是一家临床阶段的生物技术公司，专注于开发下一代 T 细胞疗法用于癌症治疗。该公司利用一个结合了细胞疗法、基因编辑和分子发现的专有平台，旨在克服治疗实体肿瘤的关键障碍。公司的方法集中在工程化 T 细胞，以增强其持久性、功能性和对免疫抑制肿瘤微环境的抵抗力。</p>
</div><p>The company's pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.</p>
<div class="lb-trans"><p>公司的产品管线包括多个自体 T 细胞项目，旨在针对黑色素瘤、卵巢癌和胰腺癌等实体恶性肿瘤中的肿瘤相关抗原。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Lyell Immunopharma</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 Lyell Immunopharma</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TFlFTA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=LYEL"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Lyell Immunopharma Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Lyell Immunopharma 吗？</h2>
</div><p>Before you consider Lyell Immunopharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Lyell Immunopharma 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lyell Immunopharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Lyell Immunopharma 并不在名单上。</p>
</div><p>While Lyell Immunopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Lyell Immunopharma 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Lyell Immunopharma (LYEL) 将在周二公布季度收益